Abstract
Chimeric antigen receptor T cell (CAR-T) therapy is a new type of immunotherapy, which has been developed rapidly in recent years. A number of clinical trials have confirmed that CAR-T therapy can effectively treat a variety of relapsed/refractory (R/R) hematological malignancies. The available results show that 70%-90% of R/R B cell acute lymphoblastic leukemia (B-ALL) patients who receive CD19 CAR-T therapy achieve complete remission (CR). However, ALL can relapse in some patients who achieved CR, and relapse has become one of the obstacles affecting the efficacy of CAR-T. The article aims to summarizes the possible mechanisms and prevention strategies of R/R B-ALL relapse after CD19 CAR-T therapy. Key words: Antigens, CD19; Receptors, antigen; Leukemia, lymphoid; Leukemia, B-cell; Immunotherapy; Recurrence; Chimeric antigen receptor T cell; B-acute lymphoblastic leukemia
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Blood Transfusion and Hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
